Evidence map›Paper›PMID 42118587›Full record

ArticleThe Journal of clinical investigation2026

IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor-induced inflammatory arthritis.

Yifei Ma, Nianqi Liu, Yan Li, Denghan Zhang, Shaohui He, Jun Lv, Yongluo Jiang, Guangmin Jian, Jingyao Zhang, Pengfei Zhu and 27 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Checkpoint inhibitors create rogue regulatory T cells.The Journal of clinical investigation · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Yifei MaDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Nianqi LiuFaculty of Psychology, Institute of Educational Science, Huazhong University of Science and Technology, Wuhan, China.
Yan LiDepartment of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Denghan ZhangDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Shaohui HeSpinal Tumor Center, Department of Orthopaedic Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Jun LvDepartment of Infectious Diseases, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yongluo JiangState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Guangmin JianDepartment of Clinical Laboratory & Key Clinical Laboratory of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jingyao ZhangDepartment of Medicine, Nuvance Health Danbury Hospital, Danbury, Connecticut, USA.
Pengfei ZhuDepartment of Clinical Laboratory & Key Clinical Laboratory of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yue MaDepartment of Laboratory Medicine, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, China.
Jiacai LinDepartment of Neurology, Hainan Hospital of Chinese PLA General Hospital, Sanya, China.
Jin LiDepartment of Anesthesiology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.
Tong WuDepartment of Ophthalmology, Hainan Hospital of Chinese PLA General Hospital, Sanya, China.
Yiwei XuDepartment of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou, China.
Xiajie LyuInternal Medicine Department, Jacobi Medical Center 1400 Pelham Play S, Bronx, New York, USA.
Youlong WangDepartment of General Surgery, Hainan Hospital of Chinese PLA General Hospital, Sanya, China.
Yiming LiDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yu Si NiuAcute Communicable Disease Epidemiology Division, Dallas County Health and Human Services, Dallas, Texas, USA.
Zhenyun GuoDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Churong LinDepartment of Radiology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Ningnan FangDepartment of Orthopedics and Spine Surgery, Cancer Hospital of Shantou University Medical College, Shantou, China.
Wei JiangInstitute of Abdominal Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Lihong WangInstitute of Abdominal Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Mengqin YuanInstitute of Abdominal Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Shenyue WangDepartment of Neurology of First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Shulin HuangSchool of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Qi HuangState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Jinjian LiDepartment of Hepatobiliary Surgery, the First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Jun LuDepartment of Hepatobiliary Surgery, the First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Bocen ChenKey Laboratory of Biochemistry and Molecular Biology, Hainan Medical University, Haikou, China.
Guanqing ZhongState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Haizhou LiuInstitute of Abdominal Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Fadian DingDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Shangeng WengDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Rui LiDepartment of Neurology of First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Ao ZhangState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUNDImmune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) significantly impairs cancer therapy and patient quality of life, yet its pathogenic mechanisms remain unclear.METHODSThrough integrated single-cell multi-omics analysis of paired peripheral blood, synovial fluid, and tumor samples from longitudinal ICI-IA cohorts and matched controls, we identified a unique regulatory T-cell (Treg) population coexpressing CD137 and IL-6R (AtpTreg).RESULTSThese cells exhibited reduced immunosuppressive capacity while aberrantly producing high levels of IL-17 and promoting proinflammatory responses of synoviocytes. AtpTreg exhibits shared clonotypes and phenotypes across tissue compartments. Notably, AtpTreg frequency correlates with increased arthritis severity yet paradoxically associates with improved overall survival. Anti-IL6R therapy reduced AtpTreg levels, corresponding with improved arthritis outcomes and quality of life, without compromising anti-tumor immunity.CONCLUSIONOur findings define a pathogenic Treg subset in ICI-IA and validate IL-6R blockade as a mechanism-based therapeutic strategy, bridging mechanistic discovery to clinical translation.TRIAL REGISTRATIONNCT07357636.FUNDINGThe National Natural Science Foundation of China General Fund Project; National Natural Science Foundation of China Youth Science Fund Project; Regional joint key support project of National Natural Science Foundation of China; Natural Science Foundation of Fujian Province; Joint Funds for the Innovation of Science and Technology, Fujian Province.

Indexed as

ArthritisImmune Checkpoint InhibitorsReceptors, Interleukin-6T-Lymphocytes, RegulatoryFemaleHumansMaleIL6R protein, humanImmune Checkpoint InhibitorsReceptors, Interleukin-6Cancer immunotherapyImmunologyOncology

Identifiers

PMID42118587
PMCPMC13318110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.